AJP Asia Intelligence Agency

Lotte Biologics Secures First Major Commercial Production Order for Songdo Plant

Lotte Biologics has secured its first major commercial production order ahead of the completion of its first plant in Songdo, Incheon. By securing customers before the factory is completed, the company has established a foundation for generating revenue from the start of operations.

Lotte Biologics announced on the 17th that it has signed a contract for contract manufacturing organization (CMO) services with a global pharmaceutical company. This order marks the first large-scale commercial production to be carried out at the Songdo Bio Campus's first plant. The names of the customer and the product, as well as the scale of the contract, were not disclosed due to confidentiality agreements. Lotte Biologics will provide a 'one-stop service' for the customer's main products, handling everything from the production of clinical raw materials to finished pharmaceuticals.

With this contract, the Songdo first plant will fill the necessary volume for initial operations after its completion. In the contract development and manufacturing organization (CDMO) industry, it is common to pursue significant orders only after the factory is fully constructed. Lotte Biologics emphasizes the significance of attracting major customers from the design and construction phase, thereby reducing this gap.

The Songdo first plant features a production facility with a capacity of 120,000 liters, equipped with eight stainless steel bioreactors of 15,000 liters each. The goal is to commence full-scale commercial production next year. The company is expanding its supply chain with a 'dual site' strategy that combines the commercial production experience from its Syracuse Bio Campus with the large-scale production capabilities in Songdo. The Syracuse campus has received over 62 regulatory approvals and has not received any issues during recent inspections by the U.S. Food and Drug Administration (FDA). The company plans to apply this quality management system to the Songdo facility as well.

James Park, CEO of Lotte Biologics, stated, "This contract demonstrates that Lotte Biologics is positioning itself as a key supply chain partner for global customers, moving beyond being a mere new entrant in the CDMO sector. We will actively support our customers' successful commercialization of new drugs based on our accumulated quality competitiveness and stable supply capabilities."

Meanwhile, Lotte Biologics will hold a completion ceremony for the Songdo first plant on the 18th. With the combined production capacity of the Syracuse plant, which will increase to 160,000 liters, securing orders to support this capacity is expected to be a prerequisite.

However, the company's performance continues to be lackluster. Lotte Biologics reported third-quarter revenues of 48.5 billion won and a quarterly net loss of 184.9 billion won. Compared to the same period last year, revenues decreased by 68.61%, and the net loss widened from 60.4 billion won.



* This article has been translated by AI.